Tag: Athena Bioscience

Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S.

MONMOUTH JUNCTION, N.J. and ATHENS, Ga., Feb. 22, 2021 /PRNewswire/ — Tris Pharma, Inc. (“Tris”) and Athena Bioscience LLC (“Athena”) announced today that they have entered into an agreement by which Athena received exclusive rights to commercialize a long-acting antihypertensive product developed using  Tris’ proprietary technology. On average, only 50% of adults adhere to chronic […]